Psychopathy has long been considered untreatable. The purpose of this paper is to provide a report from the field on therapeutic gains made in the case of a psychopathic personality and to outline what appear to be the most effective aspects of the treatment, as well as to help integrate current psychedelic research and theory with psychoanalytic theory. These therapeutic factors include:...
We are currently living through a period of ‘psychedelic renaissance’, with an increased interest, both in clinical research and in society at large, in the use of psychedelic substances such as LSD, psylocybin, DMT and mescaline. This interest, however, has recently led to an increased influx of venture capital and a fast emerging psychedelic start-up ecosystem. In this article, I will discuss...
Serotonergic hallucinogens also referred to as psychedelics, are psychoactive substances that profoundly alter perception, mood, and cognitive processes. These substances, historically intertwined with religious and cultural rituals, offer profound effects that extend beyond mere hallucinations to profoundly altered states of consciousness. Notable compounds like Lysergic acid diethylamide...
ABSTRACTBackground: Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. However, amid renewed scientific and public interest, policy remains restrictive. Existing reviews have made progress in synthesizing the results of studies of psychedelic interventions, especially psilocybin, and particularly with...
Abstract This chapter introduces the book's central question: what is a psychedelic experience? Upon reviewing the exchanges between Aldous Huxley and Humphry Osmond concerning their introduction of the term 'psychedelic', the chapter proposes that we should understand the notion along the lines they intended. Their idea was that substances such as psilocybin and LSD induce experiences that...
ABSTRACT Classical psychedelic drugs are thought to increase excitability of pyramidal cells in prefrontal cortex via activation of serotonin 2 A receptors (5-HT2 A Rs). Here, we instead find that multiple classes of psychedelics dose-dependently suppress intrinsic excitability of pyramidal neurons, and that extracellular delivery of psychedelics decreases excitability significantly more than...
Cultura y DrogaOctober 19, 2023Camila Suárez, Santiago Quintero, Juan Miguel Cardona Gil
El artículo presenta una caracterización preliminar de las prácticas y experiencias de consumo de microdosis de hongos psilocibios en Colombia. Para ello, se realizó un estudio mixto que combinó el análisis estadístico de los datos preliminares de la primera encuesta nacional sobre consumo de microdosis de psicodélicos y el análisis temático de las bitácoras de 19 usuarios que registraron...
Este artículo de reflexión sobre microdosificación con psilocibina se hizo con base en estudios observacionales, ensayos clínicos, una revisión sistemática y un estudio sociológico. La búsqueda se hizo en Pubmed usando los descriptores “psilocybin” y “microdosing”. Se tomaron artículos desde 2019 hasta enero de 2023, en inglés, enfocados en la microdosificación con psilocibina y principalmente...
Esta investigación ha examinado la evidencia histórica y arqueológica sobre los usos rituales de los hongos sagrados en Mesoamérica, específicamente en las antiguas culturas maya, mixteca y mexica, con base en el análisis de fuentes primarias como: códices, esculturas y manuscritos coloniales para lograr un mejor entendimiento de la cosmovisión de los pueblos originarios. Se trata de un estudio...
Disclosures of Financial or Other Potential Conflicts of Interest: Dr. Barnett holds stock options in CB Therapeutics. He also serves on advisory boards for CB Therapeutics and Compass Pathways. He receives monetary compensation from DynaMed Plus (EBSCO Industries, Inc.) for editorial work and from Janssen Pharmaceuticals for consulting services. Dr. Barnett has received research funding from...